Skip to main content
Clinical Trials/CTRI/2024/02/062867
CTRI/2024/02/062867Not yet recruitingPhase 4

A prospective randomized study to evaluate the effects of intrathecal magnesiumsulphate as an adjuvant to Bupivacaine hydrochloride in spinal anaesthesia. - NI

Anupama Kumari0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 4
Status
Not yet recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1.Adult patients ranging from 18-65 years of age
  • 2.Patients undergoing infra-umbilical surgeries
  • 3.Patients belonging to ASA grade 1 and 2

Exclusion Criteria

  • 1.Patients refusal, uncooperative patients or children
  • 2.Patients with hepatic, renal, cardiac or respiratory problems.
  • 3.Patients with localised site infections
  • 4.Haematological, bleeding disorders and coagulopathies.
  • 5.Known allergy to magnesium sulphate or other study drugs.

Investigators

Sponsor
Anupama Kumari

Similar Trials